Veledimex
- Generic Name
- Veledimex
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H38N2O3
- CAS Number
- 1093130-72-3
- Unique Ingredient Identifier
- ASU841TV0X
- Background
Veledimex has been used in trials studying the treatment of Glioblastoma Multiforme, Metastatic Breast Cancer, and Anaplastic Oligoastrocytoma.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT04006119
- Locations
- ๐บ๐ธ
Cedars Sinai, Los Angeles, California, United States
๐บ๐ธBaptist MD Anderson Cancer Center, Jacksonville, Florida, United States
๐บ๐ธUniversity of California - San Francisco, San Francisco, California, United States
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 1
- Registration Number
- NCT03740724
- Locations
- ๐บ๐ธ
Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03679754
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธNYU - Langone Health, New York, New York, United States
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT03636477
- Locations
- ๐บ๐ธ
University of Minnesota, Minneapolis, Minnesota, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT02423902
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT02026271
- Locations
- ๐บ๐ธ
Cedars-Sinai, Los Angeles, California, United States
๐บ๐ธUniversity of California - San Francisco, San Francisco, California, United States
๐บ๐ธNorthwestern, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.